Quick Answer
Xilio Therapeutics, Inc. reported Shares Outstanding of 4.53 million shares for fiscal year 2025.
Xilio Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 4.53M | +38.6% |
| 2024 | 3.27M | -88.2% |
| 2023 | 27.61M | +0.7% |
| 2022 | 27.43M | +0.2% |
| 2021 | 27.36M | +3865.4% |
| 2020 | 689,929 | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 51.83M | +17.9% | +0.0% |
| June 30, 2025 | 51.83M | +17.9% | +0.1% |
| March 31, 2025 | 51.78M | +50.2% | +13.2% |
| December 31, 2024 | 45.76M | +65.7% | +4.1% |
| September 30, 2024 | 43.96M | +59.7% | +0.0% |
| June 30, 2024 | 43.95M | +59.7% | +27.5% |
| March 31, 2024 | 34.47M | +25.6% | +24.9% |
| December 31, 2023 | 27.61M | +0.7% | +0.3% |
- Xilio Therapeutics, Inc. showed an increase of +38.6% in Shares Outstanding compared to the prior fiscal year.
- Over the 2020–2025 period, Xilio Therapeutics, Inc.’s shares outstanding has grown by 556.7% (from 689.9 thousand shares to 4.53 million shares).
- The most recent figure is from Xilio Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: